News

Stock of the day : Buy Laurus Labs For Target Rs. 415 - Religare Broking Ltd Laurus Labs * Laurus Labs has registered a breakout from a bullish Cup and Handle price pattern with noticeable volumes. * Stock has reclaimed its key moving averages, adding to the positivity * The recent price action combined with uptick in volumes indicates up move to continue. * We thus recommend creating fresh longs in the mentioned zone. Buy Laurus Lab CMP 384.35; Range 382-385; SL 368; Target 415   To Read Complete Report & Disclaimer Cl...
Stock of the day : Buy Laurus Labs For Target Rs. 415 - Religare Broking Ltd
Stock of the day : Buy Laurus Labs For Target Rs. 415 - Religare Broking Ltd
Source: Religare Broking Ltd
4/08/2023 11:57:48 AM
Laurus labs surges on inking pact with IIT Kanpur Laurus Labs is currently trading at Rs. 368.80, up by 1.20 points or 0.33% from its previous closing of Rs. 367.60 on the BSE. The scrip opened at Rs. 369.95 and has touched a high and low of Rs. 370.60 and Rs. 363.95 respectively. So far 25892 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 605.50 on 18-Aug-2022 and a 52 week low of Rs. 279.65 on 28-Apr-2023. Last one week high and low of the scrip stood at Rs....
Laurus labs surges on inking pact with IIT Kanpur
Laurus labs surges on inking pact with IIT Kanpur
Source: Accord Fintech
19/06/2023 12:32:51 PM
Laurus Labs moves up on getting EIR from USFDA for Andhra Pradesh manufacturing facility Laurus Labs is currently trading at Rs. 368.95, up by 2.15 points or 0.59% from its previous closing of Rs. 366.80 on the BSE. The scrip opened at Rs. 368.95 and has touched a high and low of Rs. 371.45 and Rs. 366.80 respectively. So far 34287 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 605.50 on 18-Aug-2022 and a 52 week low of Rs. 279.65 on 28-Apr-2023. Last one week high and low of the scrip stood at Rs....
Laurus Labs moves up on getting EIR from USFDA for Andhra Pradesh manufacturing facility
Laurus Labs moves up on getting EIR from USFDA for Andhra Pradesh manufacturing facility
Source: Accord Fintech
16/06/2023 10:40:40 AM
Hold Laurus Labs Ltd For Target Rs. 300 - ICICI Direct About the stock: Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs. • It owns 11 manufacturing units (six FDA approved sites) with 74 DMFs, 32 ANDAs filed (15 Para IV, 11 first to file) and 192 patents granted. • Laurus acquired Richore Life Sciences to diversify in recombinant animal origin free products, enzymes as well as building biologics custom synthesi...
Hold Laurus Labs Ltd For Target Rs. 300 - ICICI Direct
Hold Laurus Labs Ltd For Target Rs. 300 - ICICI Direct
Source: ICICI Direct
22/05/2023 2:33:28 PM
Stock Picks : Mahindra&Mahindra Ltd and Laurus Labs Ltd By ICICI Direct Mahindra&Mahindra Ltd Buy Mahindra&Mahindra Ltd @1242-1246 CMP 1245.45; Target 1262.00; Stop Loss 1231.70   Laurus Labs Ltd Buy Laurus Labs Ltd @333.50-334.50 CMP 334.15; Target 338.80; Stop Loss 330.70   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183...
Stock Picks : Mahindra&Mahindra Ltd and Laurus Labs Ltd By ICICI Direct
Stock Picks : Mahindra&Mahindra Ltd and Laurus Labs Ltd By ICICI Direct
Source: ICICI Direct
10/05/2023 11:57:17 AM
Hold Laurus Labs Ltd For Target Rs.300 - ICICI Direct Slowdown in custom synthesis weighs on numbers… About the stock: Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs. * It owns 11 manufacturing units (six FDA approved sites) with 74 DMFs, 32 ANDAs filed (15 Para IV, 11 first to file) and 192 patents granted. * Laurus acquired Richore Life Sciences to diversify in recombinant animal origin free products, enzym...
Hold Laurus Labs Ltd For Target Rs.300 - ICICI Direct
Hold Laurus Labs Ltd For Target Rs.300 - ICICI Direct
Source: ICICI Direct
9/05/2023 2:39:44 PM
Laurus Labs gains on getting USFDA`s tentative approval for Oral Dispersible Film Dolutegravir Laurus Labs is currently trading at Rs. 313.45, up by 2.30 points or 0.74% from its previous closing of Rs. 311.15 on the BSE. The scrip opened at Rs. 312.05 and has touched a high and low of Rs. 313.85 and Rs. 311.60 respectively. So far 15506 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 605.50 on 18-Aug-2022 and a 52 week low of Rs. 279.65 on 28-Apr-2023. Last one week high and low of the scrip stood at Rs....
Laurus Labs gains on getting USFDA`s tentative approval for Oral Dispersible Film Dolutegravir
Laurus Labs gains on getting USFDA`s tentative approval for Oral Dispersible Film Dolutegravir
Source: Accord Fintech
3/05/2023 9:50:03 AM
Key News - GAIL india Ltd , Bajaj Finserv Ltd , Laurus Labs , Life Insurance Corporation , By ARETE Securities Key News GAIL Q3 profit slumps 92.5% YoY to ?246 cr on supply hit; revenue dips sequentially: GAIL (India) recorded a decline in profitability during December 2022 quarter on both a year-on-year and quarteron-quarter basis due to supply hit. Although, revenue was better compared to Q3 of the previous fiscal, however, down sequentially. GAIL posted a standalone net profit of ?2245.73 crore in Q3FY23. On a standalone basis, the company's Q3 PAT dipped by 92.52% from ?3,287.99 crore in...
Key News - GAIL india Ltd , Bajaj Finserv Ltd , Laurus Labs , Life Insurance Corporation , By ARETE Securities
Key News - GAIL india Ltd , Bajaj Finserv Ltd , Laurus Labs , Life Insurance Corporation , By ARETE Securities
Source: ARETE Securities Ltd
31/01/2023 9:59:32 AM
India's Laurus Labs posts 32% profit jump on demand for drug ingredients  India's Laurus Labs Ltd reported a 32.1% rise in third-quarter profit on Monday, boosted by strong demand in its businesses that make chemicals and other ingredients used in medicines. The company's consolidated profit rose to 2.03 billion rupees (nearly $25 million) in the three months ended Dec. 31, from 1.54 billion rupees a year earlier. Revenue at Laurus Labs, which also makes hepatitis C and oncology drugs, rose more than 50% to 15.45 billion rupees. Laurus Labs s...
India's Laurus Labs posts 32% profit jump on demand for drug ingredients
India's Laurus Labs posts 32% profit jump on demand for drug ingredients
Source: Reuters
30/01/2023 12:47:41 PM
Laurus Labs rises on entering into share subscription agreement with Ethan Energy India Laurus Labs is currently trading at Rs. 457.90, up by 8.55 points or 1.90% from its previous closing of Rs. 449.35 on the BSE. The scrip opened at Rs. 453.50 and has touched a high and low of Rs. 459.75 and Rs. 450.00 respectively. So far 32636 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 626.00 on 19-Apr-2022 and a 52 week low of Rs. 433.20 on 28-Jan-2022. Last one week high and low of the scrip stood at Rs....
Laurus Labs rises on entering into share subscription agreement with Ethan Energy India
Laurus Labs rises on entering into share subscription agreement with Ethan Energy India
Source: Accord Fintech
25/11/2022 10:43:28 AM
Outperform Laurus Labs Ltd For Target Rs.715 - Choice Broking Key Rationale: Laurus’s intention to achieve US$ 1Bn revenue in FY23 which is 50% growth, is expected to push the company in high growth period. Revenue mix from Custom Synthesis business is expected to grow speedily due to healthy client addition, faster commercialization of projects with existing clients and management’s focus on higher margin segments. The increased focus on Non ARV segments will pave the way for better revenue mix and improved margins. Gross margin...
Outperform Laurus Labs Ltd For Target Rs.715 - Choice Broking
Outperform Laurus Labs Ltd For Target Rs.715 - Choice Broking
Source: Choice Broking Pvt Ltd
2/05/2022 11:53:12 AM
Laurus Labs shines on signing agreement with MPP Laurus Labs is currently trading at Rs. 493.25, up by 7.80 points or 1.61% from its previous closing of Rs. 485.45 on the BSE. The scrip opened at Rs. 483.90 and has touched a high and low of Rs. 493.90 and Rs. 478.40 respectively. So far 73603 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 723.55 on 12-Aug-2021 and a 52 week low of Rs. 333.25 on 01-Feb-2021. Last one week high and low of the scrip stood at Rs....
Laurus Labs shines on signing agreement with MPP
Laurus Labs shines on signing agreement with MPP
Source: Accord Fintech
21/01/2022 10:42:07 AM
Buy Laurus Lab Ltd For Target Rs.670 - ICICI Direct Subdued Q2 amid drag in ARV APIs… About the stock: Laurus Labs operates in the segment of Generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs. * It has eight manufacturing units (five FDA approved sites) with 61 DMFs, 27 ANDAs filed (two Para IV, seven first to file), 292 patents filed (150 granted) * Laurus acquired Richore Life Sciences to diversify in area of recombinant animal origin free produc...
Buy Laurus Lab Ltd For Target Rs.670 - ICICI Direct
Buy Laurus Lab Ltd For Target Rs.670 - ICICI Direct
Source: ICICI Direct
7/12/2021 11:02:26 AM
Buy Laurus Labs Ltd For Target Rs.690 - Motilal Oswal Laurus ventures into new disruptive therapy * Laurus Labs (LAURUS) has agreed to acquire a 26.6% stake in ImmunoACT for a consideration of INR460m, implying enterprise value of INR1.7b. ImmunoACT currently has four CAR-T cell molecules, with one of them undergoing clinical trials. * CAR-T cell is a new therapy for Leukemia/Lymphoma, with USD1.5b in worldwide sales of five commercialized products. * Given that ImmunoACT products are under development, the commercialization would be su...
Buy Laurus Labs Ltd For Target Rs.690 - Motilal Oswal
Buy Laurus Labs Ltd For Target Rs.690 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
23/11/2021 10:11:26 AM
Quote on Laurus Labs Limited results by Mr. Yash Gupta, Angel One Ltd Below is quote on Laurus Labs Limited results by Mr. Yash Gupta, Equity Research Analyst, Angel One Ltd    Laurus labs reported Q2FY22 number below the market expectation. Laurus labs reported revenue from operation at ₹1,203 crores up by 5.7% YoY from ₹1138 crores in Q2FY21. Company reported a net profit of ₹197.7 crores down by 16.7% as compared to ₹237.5 crores in Q2FY21. EBITDA margins were under pressure due to an increase in other expen...
Quote on Laurus Labs Limited results by Mr. Yash Gupta, Angel One Ltd
Quote on Laurus Labs Limited results by Mr. Yash Gupta, Angel One Ltd
Source: Angel One Ltd
28/10/2021 4:24:21 PM
Buy Laurus Lab Ltd For Target Rs.785 - ICICI Direct Strong performance driven by formulations… About the stock: Laurus Labs operates in the segment of Generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs. * It has eight manufacturing units (five FDA approved sites) with 61 DMFs, 27 ANDAs filed (two Para IV, seven first to file), 292 Patents filed (150 granted) * Laurus acquired Richore Life Sciences to diversify in area of recombinant animal origin fr...
Buy Laurus Lab Ltd For Target Rs.785 - ICICI Direct
Buy Laurus Lab Ltd For Target Rs.785 - ICICI Direct
Source: ICICI Direct
30/08/2021 10:17:00 AM
Buy Laurus Labs Ltd For Target Rs.800 - Motilal Oswal Formulation/Synthesis outshines; API underperforms Building of Non-ARV drivers/capacity on track * Laurus Labs (LAURUS) 1QFY22 earnings missed our expectations. The robust performances in the Finished Dosage Formulations (FDF) and Synthesis segments were more than offset by a muted show in the Active Pharma Ingredients (API) segment. That said, in addition to having an established business in the Anti-Retroviral (ARV) segment, LAURUS is on track to build new levers for future growth i...
Buy Laurus Labs Ltd For Target Rs.800 - Motilal Oswal
Buy Laurus Labs Ltd For Target Rs.800 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
19/08/2021 10:47:58 AM
Buy Laurus Labs Ltd For Target Rs.800 - Motilal Oswal Scaling up new levers to accelerate growth Expanding the base business as well * Laurus Labs (LAURUS)’s Annual Report Analysis indicates a sharp improvement in ROE, led by a strong head-start in Finished dosage forms (FDF), improving operating profit, and a reduced interest rate. * Since its journey from ARV API to a fully integrated pharmaceutical company over FY06–21, LAURUS is on the path to strengthening its capabilities/capacity in Contract Development and Manufactur...
Buy Laurus Labs Ltd For Target Rs.800 - Motilal Oswal
Buy Laurus Labs Ltd For Target Rs.800 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
12/08/2021 10:47:51 AM
Buy Laurus Labs Ltd For Target Rs. 800 - Motilal Oswal Scaling up new levers to accelerate growth Expanding the base business as well * Laurus Labs (LAURUS)’s Annual Report Analysis indicates a sharp improvement in ROE, led by a strong head-start in Finished dosage forms (FDF), improving operating profit, and a reduced interest rate. * Since its journey from ARV API to a fully integrated pharmaceutical company over FY06–21, LAURUS is on the path to strengthening its capabilities/capacity in Contract Development and Manufactur...
Buy Laurus Labs Ltd For Target Rs. 800 - Motilal Oswal
Buy Laurus Labs Ltd For Target Rs. 800 - Motilal Oswal
Source: Motilal Oswal Financial Services
17/07/2021 10:34:22 AM
Laurus Labs gets DRDO license to manufacture 2-DG Laurus Labs Ltd on Friday announced that it has received the license from the Defence Research and Development Organisation (DRDO) to manufacture and market its Covid drug, 2-Deoxy-D-Glucose (2-DG). 2-DG has been given emergency approval by the Drug Controller General of India for use on Covid-19 patients in India. Laurus Labs, a leading research and development-driven and fully integrated pharmaceutical and biotech company, has already applied to the Central Drugs Standard Control Orga...
Laurus Labs gets DRDO license to manufacture 2-DG
Laurus Labs gets DRDO license to manufacture 2-DG
Source: IANS
3/07/2021 9:46:02 AM
Buy Laurus Labs Ltd For Target Rs.550 - Motilal Oswal Multiple levers to aid growth over next 3 years API/Synthesis drive earnings in 4QFY21 * LAURUS delivered in line performance in 4QFY21, with highest ever quarterly sales/EBITDA/PAT. Its capacity expansion program for formulation (FDF)/API remains on track. The company continues to make steady progress on building capability as well as capacity in the Synthesis/Biologics segment, which are additional growth levers for the next 4-5 years. * We raise our FY22E/FY23E EPS estimate by 6%,...
Buy Laurus Labs Ltd For Target Rs.550 - Motilal Oswal
Buy Laurus Labs Ltd For Target Rs.550 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
7/05/2021 11:58:11 AM
Laurus Labs Q4 net profit zooms 160.18% at Rs 292.78 cr The company reported standalone net profit of Rs 292.78 crore for the quarter ended March 31, 2021 as compared to Rs 112.53 crore in the same period last year, registering a year-on-year growth of 160.18 per cent. Net revenue of the company rose substantially by 68.68 per cent at Rs 1,398.74 crore in January-March quarter of this fiscal as against Rs 829.23 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 47.12 per cent to Rs 936.29...
Laurus Labs Q4 net profit zooms 160.18% at Rs 292.78 cr
Laurus Labs Q4 net profit zooms 160.18% at Rs 292.78 cr
Source: Dion Global Solutions Ltd
29/04/2021 5:03:14 PM
Stock Picks - Laurus Labs For Target Of Rs. 406 - ICICI Direct Technical Observations * The stock has formed higher base in the vicinity of 50 day EMA which has been held since April 2020 and resumed upward momentum indicating resumption of primary up trend. Thereby, offering fresh entry opportunity * The formation of higher high & higher low on larger degree charts (weekly/monthly) makes us believe, stock has further upsides in coming session. * The stock has immediate support at | 349 levels as it is 61.8% retracement of the current up mov...
Stock Picks - Laurus Labs For Target Of Rs. 406 - ICICI Direct
Stock Picks - Laurus Labs For Target Of Rs. 406 - ICICI Direct
Source: ICICI Direct
17/02/2021 2:21:39 PM
Stock Picks - Buy Laurus Labs Ltd For Target Of Rs. 406 - ICICI Direct Technical Observations * The stock has formed higher base in the vicinity of 50 day EMA which has been held since April 2020 and resumed upward momentum indicating resumption of primary up trend. Thereby, offering fresh entry opportunity * The formation of higher high & higher low on larger degree charts (weekly/monthly) makes us believe, stock has further upsides in coming session. * The stock has immediate support at | 349 levels as it is 61.8% retracement of the current up mov...
Stock Picks - Buy Laurus Labs Ltd For Target Of Rs. 406 - ICICI Direct
Stock Picks - Buy Laurus Labs Ltd For Target Of Rs. 406 - ICICI Direct
Source: ICICI Direct
15/02/2021 12:01:34 PM
Technical Positional Pick - Buy Laurus Labs Ltd For Target Rs. 440 - HDFC Securities Technical Positional Pick - Buy Laurus Labs Ltd For Target Rs. 440 - HDFC Securities  TECHNICAL OBSERVATIONS * Stock price formed multiple bottoms around 340 levels * Stock price is taking support at 50 day EMA during the last few days * Stock price has already broken out on the monthly and weekly charts * Oscillators like RSI and MFI is showing strength in the current uptrend of the stock * Primary trend of the stock is positive where it is trading above its 100- ...
Technical Positional Pick - Buy Laurus Labs Ltd For Target Rs. 440 - HDFC Securities
Technical Positional Pick - Buy Laurus Labs Ltd For Target Rs. 440 - HDFC Securities
Source: HDFC Securities Ltd
8/02/2021 12:29:15 PM
Momentum Pick - Buy Laurus Labs Ltd For Target Rs. 385 - HDFC Securities Momentum Pick - Buy Laurus Labs Ltd For Target Rs. 385 - HDFC Securities  After showing a minor declines/sideways consolidation, the stock price has shifted into an upside bounce. Today’s upmove could be considered as an upside breakout of the narrow range movement/immediate resistance. The short term trend seems to have turned positive. We observe a formation of positive candlestick pattern as per intraday/daily/weekly timeframe chart. Volume has started to ris...
Momentum Pick - Buy Laurus Labs Ltd For Target Rs. 385 - HDFC Securities
Momentum Pick - Buy Laurus Labs Ltd For Target Rs. 385 - HDFC Securities
Source: HDFC Securities Ltd
20/01/2021 2:15:05 PM
Buy Laurus Labs Ltd For Target Rs.397 - HDFC Securities Buy Laurus Labs Ltd For Target Rs.397 - HDFC Securities   Our Take: Laurus Labs is one of the world’s leading suppliers of Anti-Viral APIs and intermediates. Laurus has leveraged its API skills and forward integrated capabilities to supply finished dosage formulations in regulated and semi-regulated markets. Its strategic and early investments in R&D and manufacturing infrastructure matched with the spurt in demand for HIV drugs in low and middle-income countries...
Buy Laurus Labs Ltd For Target Rs.397 - HDFC Securities
Buy Laurus Labs Ltd For Target Rs.397 - HDFC Securities
Source: HDFC Secruties Ltd
14/01/2021 12:40:01 PM